Drug Profile
Research programme: CNS infections therapy - Cangene
Alternative Names: CNS infections therapy research programme - CangeneLatest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Cangene Corporation
- Developer Sanofi
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Encephalitis virus infections; Rabies
Most Recent Events
- 21 Jul 2005 Discontinued - Preclinical for Encephalitis virus infections in Canada (unspecified route)
- 21 Jul 2005 Discontinued - Preclinical for Rabies in Canada (unspecified route)
- 27 Oct 2004 Preclinical trials in Encephalitis virus infections in Canada (unspecified route)